Evidence map›Paper›PMID 28160213›Full record

Trial reportInternational journal of hematology2017

A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan.

Yoshiaki Ogawa, Koji Izutsu, Toru Kiguchi, Ilseung Choi, Yoshifusa Takatsuka, Kiyoshi Ando, Junji Suzumiya, Japanese Bendamustine CLL Study Group

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yoshiaki OgawaDepartment of Hematology and Oncology, Tokai University Hospital, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. yoshioga@is.icc.u-tokai.ac.jp.
Koji IzutsuDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Toru KiguchiDepartment of Hematology, Chugoku Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuyama, Japan.
Ilseung ChoiDepartment of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Yoshifusa TakatsukaDepartment of Hematology, Jiaikai Imamura Bun-in Hospital, Kagoshima, Japan.
Kiyoshi AndoDepartment of Hematology and Oncology, Tokai University Hospital, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Junji SuzumiyaDepartment of Oncology/Hematology, School of Medicine, Shimane University, Izumo, Japan.
Japanese Bendamustine CLL Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study was intended to examine the efficacy and safety of bendamustine monotherapy in patients with previously untreated chronic lymphocytic leukemia (CLL) for whom treatment with fludarabine (FLU) was not suitable, and in FLU-naïve patients with relapsed/refractory CLL. We intravenously administered bendamustine 100 mg/m

Indexed as

AgedAntineoplastic Agents, AlkylatingBendamustine HydrochlorideFemaleHumansInfusions, IntravenousJapanLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedTreatment OutcomeAntineoplastic Agents, AlkylatingBendamustine HydrochlorideBendamustineChronic lymphocytic leukemiaEfficacyJapaneseSafety

Identifiers

PMID28160213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.